Abstract
Introduction

Ovarian cancer is the leading cause of gynaecological cancer mortality. Its treatment usually consists of optimal cytoreductive surgery and platinum-based combination chemotherapies. Although the platinum compounds cisplatin and carboplatin are among the most effective anticancer drugs, development of resistance to the platinum-based therapies has emerged as a major obstacle in the treatment of ovarian cancers. As a result, the 5-year survival rate for advanced ovarian cancer (stages III and IV) is only about 20-30%
. It [7] . Further studies demonstrated that the expression of annexin A3 is also significantly increased in tumours from platinum-resistant ovarian cancer patients [8] .
Moreover, enforced expression of annexin A3 specifically conferred platinum resistance to ovarian cancer cells both in culture and in an animal model, whereas down-regulation of annexin A3 in the platinum-resistant ovarian cancer cells made them more sensitive to cisplatin [8]. These results indicated that increased annexin A3 plays a critical role in platinum resistance and raised the possibility that it could be a biomarker for resistance to platinum-based therapies in ovarian cancer patients.
Annexins [10] . These activities appear to be responsible for the diversified functions of annexins, which include mediating the anti-inflammation action of glucocorticoids, participating in the regulation of blood coagulation and modulating ion channel transportation [11] . In addition, the ability of annexin A5 to bind phosphatidylserine also makes it a valuable tool to detect apoptotic cells [12] . However, there are relatively few studies on the functions of annexin A3, the 36-kD protein expressed in the cytoplasm of many cells [13] . 
Materials and methods
Cell lines and culture conditions
Immunoblotting
Immunoblotting was performed as described [14] . Briefly 
Transmission electron microscopy (TEM)
Cells were fixed and processed as described [16] . 
Immunoelectron microscopy (IEM)
IEM was performed as described with a few modifications [17] [18] The annexin A3 levels of individual patients are shown in Figure  1C and Table 1 Fig. 2A) . (Fig. 2B) , indicating that they participate in exocytosis. (Fig. 2C, (Fig. 3) . As shown in Figure 3B , the high-density gold particles that are indicative of annexin A3 were present in the cytoplasmic region of the cells. Particularly, annexin A3 appeared to be highly expressed both around and inside the membrane of the vesicles. Pictures taken under higher magnification showed that some annexin A3-containing vesicles appear to be fusing with cell membranes (Fig. 3C and 3D) , indicating that annexin A3 might be secreted through exocytosis. demonstrated that annexin A3 is associated with these exosomes (Fig. 4B and C) . However, because of the size of the gold particle (12 nm) , it is difficult to determine whether annexin A3 is associated with the exosome membrane. The association of annexin A3 with these exosomes was further examined by anti-annexin A3 immunoblotting. As shown in Figure 4D , exosomes from SKOV3 cells contain both annexin A3 and the characteristic hsp70. These results indicate that at least some annexin A3 is secreted through exocytosis inside the exosomes. The amount of exosomes released from various ovarian cancer cells was further assessed by measuring total protein in exosome preparations. As shown in Figure 5A , enforced expression of annexin A3 significantly increased the amount of exosome released, whereas down-regulation of annexin A3 in platinum-resistant cells reduced exosome release significantly. The same phenomenon was observed when exosome preparations were analysed by immunoblotting with anti-hsp70 and annexin A3 antibodies (Fig. 5B) .
Expression of annexin A3 is associated with the increased cytoplamic vesicles
It has been shown in a variety of cells that annexins can affect vesicle trafficking and exocytosis by promoting membrane fusion [24]. Therefore, we examined the ultrastructure of the ovarian cancer cells using TEM. The cell nucleus, many organelles in cytoplasm, and the cell membrane could be clearly identified under TEM (10,000ϫ). Compared with that of platinum-sensitive SKOV3 and A2780 cells, the cytoplasm of platinum-resistant cells SKOV3/Cis and A2780/Cis contains significantly increased numbers of membrane-bound round or elliptical vesicles, ranging from 0.1 to 1 m in size. Some of these vesicles contain high-density particles, suggesting that they may be related to phagocytosis or endosomes (
Under higher magnification (50,000ϫ), it is evident that some of the vesicles look like multivesicular bodies (MVBs) with contents of various densities. Some vesicles can be found fusing with cell membrane
Interestingly, SKOV3/Ann and A2780/Ann, the ovarian cancer cells that were transfected with an annexin A3-expressing vector, also possess increased numbers of vesicles (Fig. 2C). Furthermore, SKOV3/Cis/R and A2780/Cis/R, the platinumresistant cell lines that had been transfected with a vector expressing an antisense annexin A3 and had reduced levels of annexin A3, also had fewer vesicles
lower). These results demonstrate that increased expression of annexin A3 in the ovarian cancer cells results in the formation of increased numbers of MVBs in the cytoplasm. To further explore the association of annexin A3 secretion and the cytoplasmic vesicle, cells were examined by IEM using an anti-annexin A3 antibody and a colloidal gold-labelled secondary antibody. To avoid its potential effect on antibody-recognized epitopes of annexin A3, osmic acid was not used in the staining of cells for electron microscopy. Therefore, the pictures from these studies are lighter and have less contrast compared to regular TEM pictures. Nevertheless, the increased numbers of the vesicles could be identified in SKOV3/Cis cells under this condition
000ϫ). The high-density 12-nm colloidal gold particles, which are indicative of annexin A3, could be observed in the cytoplasm of the cells (small arrows). Some gold particles existed in or around vesicles (medium arrows). (A) Control (sections were treated as described without antiannexin A3 antibody). (B)
Annexin
Discussion
We have found in this study that annexin A3 can be secreted from ovarian cancer cells. Up-regulation of annexin A3 in these cells leads to a significant increase in its secretion, whereas down-regulation of annexin A3 results in its reduction in culture medium. This is consistent with the observation that annexin A3 can be detected in urine from prostate cancer patients [22] [23, [26] [27] . Furthermore, it has been shown that annexin A2 is associated with MVBs in enterocytes [26] , suggesting that exocytosis of MVBs might be a common mechanism for annexin secretion. This has been further supported by the finding that annexins are components of exosomes from a variety of cells [28] .
We also examined the levels of annexin A3 in sera from 30 [29] , in lung adenocarcinoma with lymph node metastasis [30] and in prostate tumours [31] [32] . Because we have shown previously that annexin A3 specifically confers resistance to the platinum compounds [8] , it is also conceivable that the insensitivity to platinum-based chemotherapy in some patients is because of resistance to other agents such as paclitaxel [33, 34] .
Two recent studies have found that, when compared with other types of ovarian cancer, annexin A4 is up-regulated in ovarian clear cell carcinomas and is associated with platinum resistance [35, 36] . Given the structural and functional similarities among the annexin family members, it is conceivable that annexins A3 and A4 may act through similar mechanisms in ovarian cancer cells. We are also interested in examining the expression of additional annexins in various types of ovarian cancers. It has been reported that annexin A3 in urine detected by immunoblotting is a highly specific marker for early detection of prostate cancer [22] . Given level, we are interested in examining annexin A3 in urine from ovarian cancer patients in the future. In addition to the 36-kD annexin A3 that we investigated in this study, a 33-kD alternatively spliced form of annexin A3 has been found in primary cell cultures from renal cell carcinoma and normal renal cortex tissue [37] . Intriguingly, although 36-kD isoform was down-regulated in renal cell carcinoma, the 33-kD isoform was up-regulated in these tumour cells [37] . We 
